Innovus Pharma Announces The Beginning Of Patient Enrollment In Its Post-Marketing Ejectdelay™ Clinical Study In The Middle East

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 15, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCBB:INNV) today announced that patient enrollment has begun in its EjectDelay™ post-marketing clinical study in Lebanon. The study is being run at the Lebanese-Canadian Hospital in Beirut, Lebanon.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC